CELLINK AB (publ) has received an order for consumables for healthcare through an order from the National Board of Health and Welfare in Sweden, the order value is a total of 5 200 000 SEK. Since the company has expertise and capacity to produce various gels used in the company's bioink products, CELLINK has in recent weeks been working to adjust parts of the production to help with the current situation with COVID-19, including the production of hand sanitizers and test equipment such as qPCR instruments and reagents. The order shall be delivered during the company's third quarter.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone (Sweden): +46 73 267 00 00 Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138
CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the Company’s certified adviser, available by phone at +46 846 383 00 and by email at: [email protected]